Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic
Novel source of stem cells in full-term amniotic fluid provides basis for broad pipeline
Lund, Sweden, July 12, 2021: Amniotics AB (publ) (”Amniotics” or the “Company”), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market The offering was fully subscribed and attracted widespread interest from Swedish investment companies and family offices as well as the general public in Sweden, Norway and Finland. The funds will now be deployed to advance the company’s preclinical portfolio of cell therapy candidates based on mesenchymal